|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.IN |
First Approval Date31 May 2023 |
|
Mechanismendothelin receptor antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Endogenx, Inc.
0 Patents (Medical) associated with Endogenx, Inc.
100 Deals associated with Endogenx, Inc.
100 Translational Medicine associated with Endogenx, Inc.